These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20506353)

  • 1. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
    Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
    Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
    Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
    Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
    Mariette X; Gottenberg JE; Ravaud P; Combe B
    Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
    Wolfe F; Caplan L; Michaud K
    Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice.
    Toussirot E; Pertuiset E; Sordet C; Augé B; Wendling D; Pallot-Pradès B; Collet P; Lohse A; Balblanc JC
    Joint Bone Spine; 2010 Mar; 77(2):142-5. PubMed ID: 20171921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry.
    Bader-Meunier B; Decaluwe H; Barnerias C; Gherardi R; Quartier P; Faye A; Guigonis V; Pagnier A; Brochard K; Sibilia J; Gottenberg JE; Bodemer C;
    J Rheumatol; 2011 Jul; 38(7):1436-40. PubMed ID: 21677003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
    Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
    Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of infection in rheumatoid arthritis.
    Doran MF; Crowson CS; Pond GR; O'Fallon WM; Gabriel SE
    Arthritis Rheum; 2002 Sep; 46(9):2294-300. PubMed ID: 12355476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.